Michael Jorrin, "Doc Gumshoe"

Author Bio

Michael Jorrin,
I have been a medical writer for about 25 years; before that I was a documentary film maker, and some of my films were about medical subjects. I am not a physician, but I have a pretty good scientific background. I wouldn’t dream of recommending any kind of treatment to anyone, and I cannot give medical advice. However, I understand the medical literature and the data and evidence behind it, and I have an inquiring and skeptical turn of mind. I scrutinize and question and, sometimes, challenge the positions of some of the established health-care organizations as well as the marketers of health information. Eternal vigilance is a small price to pay for health. — Michael Jorrin (aka DocGumshoe) Michael Jorrin is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

Doc Gumshoe – Short & Easy Bits

This particular bit of news leaves your friend Doc Gumshoe shaking his head in puzzlement.  To wit, in the US it is expected that there will be a substantial shortage of physicians in the upcoming years.   The American Association of Medical Colleges predicts that this shortage may reach about 122,000 physicians by the year […]

Cancer: the Changing Landscape in 2019

The publicity material for M. D. Anderson in Houston, Texas, which is perhaps the leading cancer treatment center in the United States, frequently includes a statement to the effect that they are committed to “ending cancer.” That statement puts me in mind of maps dating from the first century AD, in which large unexplored areas […]

Why We Take the Bait

One would think that it would take a person of normal intelligence about half a minute to conclude that lures such as the ones below could not possibly be on the up and up.   Here’s one.  It starts out with a note from Christine O’Brien. “The Sovereign Investor Daily A brand new, ‘Alzheimer’s vaccine’ […]

In Defense of the Egg

Doc Gumshoe is not in the habit of contradicting the conclusions, backed by research, that are stated in papers published by the Journal of the American Medical Association, commonly referred to as JAMA.    JAMA is, after all, one of a handful of the most prestigious medical journals on the planet, along with the New […]

Short Bits for a Short Month

“For such a beastly month as February, 28 days as a rule are plenty,” said the Pirate King.   But you would be surprised at the number of interesting snippets of news in the health-care realm that landed in my inbox during this short month.   I’ll lead off with one that gave me a particular kick. […]

Rapid Response: The Israeli Cure for All Cancers? And a Postscript on Opioids

What set me off on this rant was the very first comment on the piece that posted on January 31st, “Looking Backward – And a Peek in the Other Direction.”   Here’s the comment: “Thanks, Doc. Hope you will comment on the news out of Israel this week: https://www.jpost.com/HEALTH-SCIENCE/A-cure-for-cancer-Israeli-scientists-say-they-think-they-found-one-578939” Naturally, I looked, and what I found […]

Ketamine: Menace or Miracle?

I’ll grant that my headline is meant to be catchy and induce you to read this epistle.   Some of you will ask what is ketamine anyway, and most of you will know from the get-go that ketamine, whatever the heck it is, will turn out to be neither a menace nor a miracle, but something […]

Cancer Treatment 2018: Looking Towards the Future

Most of the attention in the media is now focused on the several forms of cancer treatment grouped under the flattering term “Precision Medicine.”   I find that the term raises my skepticism index just a bit; it’s like eating establishments labeling themselves “Gourmet Restaurants,” the implication being that joints not so identified are just […]

Cancer: The Lay of the Land in 2018

Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me.   Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy?   But I probably pay more attention to […]

Recent Author Comments

On A Look at the Promise of Gene Editing
It was not Travis that got it wrong, but Yours Truly Doc Gumshoe (Michael Jorrin). I was thinking of purines and pyrimidines when I made that blunder. Thanks for putting me back on course.[...]
On Recent Comments: Responses and Reflections
All correct, but why should it affect pilots more than other people? By the way, the amyloid plaque hypothesis just got dealt another blow - a woman with an APOE variant that in her immediate family has led to disastrously early AD (in their 40s) was fr[...]
On Recent Comments: Responses and Reflections
Many thanks! Oxygen depletion could certainly affect cognition, along with other physiologic consequences. Have no clue as to whether the long-term effects could be permanent dementia or Alzheimer's.[...]
On Recent Comments: Responses and Reflections
Certainly don't mean to shortchange you, but Im not coming to any definite conclusions on Anavex 2-73 in advance of definitive data. I won't deny that there are promising signs, but that has been the case with many other prospective AD drugs which eventu[...]
On Alzheimer’s Disease: 2019 Refresher and Updates
I haven't checked up on Anavex lately, but will do so. Thanks.[...]
On Friday File: One Sell, One Short, A few add-on Buys... plus some quarterly updates
Take the Kweichow Moutai loot & buy some Talisker or perhaps Uigeadail . Best, MJ[...]
On Solving the Healthy Returns pitch: "Retire 10 TIMES RICHER" -- What's their "#1 Best Biotech to Cure Your Retirement Money Worries?"
Esperion has worked hard to get bempedoic acid & the ezetimibe-bempedoic combo to the point where the FDA green light is likely. But then it will take its place in the running with the statins & other anticholesterol agents, which are cheaper & work fin[...]
On Cancer: the Changing Landscape in 2019
So far, nothing has been published about HAMLET's drug, named Alpha !A. All we know is that the company has characterized the results of their Phase 1/2 trial as favorable. Caveat emptor![...]
On Cancer: the Changing Landscape in 2019
This is a reply to your previous comment. The answer is YES, i had a prostate biopsy in 2002 & then a prostatectomy about three months late. The whole thing was unremarkable. My PSA levels continue to be undetectable. But that was me. Every pe[...]
On Cancer: the Changing Landscape in 2019
I have had two colonoscopies since my 75th birthday and I'm due for another one in 2020. The underlying concern is with the patient's life expectancy; mine appears to be pretty good. I'll check into ColoGuard.[...]
On Cancer: the Changing Landscape in 2019
I will try to check into those - thanks for the hint.[...]
On In Defense of the Egg
... but without Investing Gumshoe there would be no Doc Gumshoe![...]
On In Defense of the Egg
I'm gratified by the volume and tone of the comments, thanks very much. Can't respond to any in particular today - have to go to a funeral & then the dress rehearsal for our chorus's Saturday concert. I'll make a note of the many suggestions for furthe[...]
On What's Curzio's "The End of Heart Disease" Stock and its "One Simple Device?"
Oh, my! Omron also makes a fairly reliable BP device, surely more accurate that a watch, for about seventy bucks. A continuous BP device is perhaps valuable in a very few people, but BP should be measured at rest for the readings to have any value, sin[...]
On Blanco's " $2 Trillion 'Bio-Switch'" Stock -- he says it's "Hailed as Miracle Drug for 3 Killer Diseases"
Many pharm outfits - Novartis, for one - are researching epigenetics, which is indeed a promising field. There will certainly be many drugs based on that mechanism. Does Resverlogix have an inside track? Just possibly.[...]
On Rapid Response: The Israeli Cure for All Cancers? And a Postscript on Opioids
As always, thanks for the comments. I can see that I have my work cut out - several interesting suggestions to look into. Best to all, Michael Jorrin (AKA Doc Gumshoe[...]
On Looking Backward – And a Peek in the Other Direction
I can't say whether it would be "profitable" to look into either of those two enterprises. It's very early days for both. MRI imaging has been combined with precisely targeted radiation therapy for several years and has led to great improvements in out[...]
On Looking Backward – And a Peek in the Other Direction
I've never heard of that particular one, but "a cure for every cancer" is exceedingly unlikely. A tiny bit of digging came up with this, published in Forbes: “As someone with 10 years of molecular biology and medical experience, I strongly suspect th[...]
On Skousen's "American X" Company knows how to kill a $40 billion disease... what is it?
Pfizer had four new drug approvals in 2018 and is looking quite strong looking forward, in addition to which they have many irons in the fire. I can't see that Dekavil is going to make a huge difference. And as for turning off the part of the immune re[...]
On Ketamine: Menace or Miracle?
Sorry about your experience! Were you already on a pain killer when they added the ketamine? There is clearly a lot more to be learned about the whole subject.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch